New Diabetes Drug Shows Effectiveness

Tuesday, 16 Apr 2013 12:15 PM

 

  Comment  |
   Contact  |
  Print   |
    A   A  
  Copy Shortlink
Eli Lilly and Co said two additional late-stage studies testing its experimental diabetes drug dulaglutide met the main goal of reducing hemoglobin A1c levels, a measure of blood sugar.
 
Along with positive results from three other late-stage trials announced in October, the data will support a marketing application for dulaglutide, Lilly said in a statement.
 
In the study named AWARD 2, the company said a 1.5 mg dose of its drug proved superior to Sanofi's Lantus, at 52 weeks in Type 2 diabetes patients, who are already on two other diabetes drugs, metformin and glimeperide.
 
Dulaglutide also trumped insulin lispro, in combination with Lantus, at 26 weeks of treatment in a study dubbed as AWARD 4, Lilly said.
 
The company said the most frequently reported adverse events were gastrointestinal.
 
In October, Lilly reported positive results of the other three studies in which dulaglutide was compared with other diabetes medications.

© 2014 Thomson/Reuters. All rights reserved.

  Comment  |
   Contact  |
  Print   |
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Diagnose Your Kid's Ear Infection With Your iPhone

Friday, 19 Dec 2014 16:15 PM

Diagnosing your kid's ear infections might soon be as simple as taking a video on your smartphone. . . .

Revlon Removing Some Dangerous Chemicals From Cosmetics

Friday, 19 Dec 2014 16:11 PM

Revlon announced that it will no longer use two chemical ingredients in its products, responding to a consumer petition  . . .

New Ovarian Cancer Drug Gets FDA OK

Friday, 19 Dec 2014 15:48 PM

The U.S. Food and Drug Administration has approved a new drug to treat advanced ovarian cancer, along with a test to ide . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved